Cargando…
Frailty Status and Polypharmacy Predict All-Cause Mortality in Community Dwelling Older Adults in Europe
European population ageing is associated with frailty, a complex geriatric syndrome, and polypharmacy, both resulting in adverse health outcomes. In this study we aimed to evaluate the impact of frailty and polypharmacy, on mortality rates, within 30 months, using a cohort of SHARE participants aged...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8036295/ https://www.ncbi.nlm.nih.gov/pubmed/33808273 http://dx.doi.org/10.3390/ijerph18073580 |
_version_ | 1783676876652281856 |
---|---|
author | Midão, Luís Brochado, Pedro Almada, Marta Duarte, Mafalda Paúl, Constança Costa, Elísio |
author_facet | Midão, Luís Brochado, Pedro Almada, Marta Duarte, Mafalda Paúl, Constança Costa, Elísio |
author_sort | Midão, Luís |
collection | PubMed |
description | European population ageing is associated with frailty, a complex geriatric syndrome, and polypharmacy, both resulting in adverse health outcomes. In this study we aimed to evaluate the impact of frailty and polypharmacy, on mortality rates, within 30 months, using a cohort of SHARE participants aged 65 years old or more. Frailty was assessed using a version of Fried’s phenotype criteria operationalized to SHARE while polypharmacy was defined as taking five or more drugs per day. We found a prevalence of 40.4% non-frail, 47.3% pre-frail and 12.3% frail participants. Moreover, a prevalence of polypharmacy of 31.3% was observed, being 3 three times more prevalent in frail individuals and two times in pre-frail individuals, when compared with non-frail. Individuals with both conditions had shown higher mortality rates. Comparing with non-polymedicated non-frail individuals all the other conditions are more prone to die within 30 months. Polymedicated older and male participants exhibited also higher mortality rates. This work shows polypharmacy and frailty to be associated with a higher risk of all-cause of mortality and highlights the need to decrease ‘unnecessary’ polypharmacy to reduce drug-related issues and also the need to assess frailty early to prevent avoidable adverse outcomes. |
format | Online Article Text |
id | pubmed-8036295 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-80362952021-04-12 Frailty Status and Polypharmacy Predict All-Cause Mortality in Community Dwelling Older Adults in Europe Midão, Luís Brochado, Pedro Almada, Marta Duarte, Mafalda Paúl, Constança Costa, Elísio Int J Environ Res Public Health Article European population ageing is associated with frailty, a complex geriatric syndrome, and polypharmacy, both resulting in adverse health outcomes. In this study we aimed to evaluate the impact of frailty and polypharmacy, on mortality rates, within 30 months, using a cohort of SHARE participants aged 65 years old or more. Frailty was assessed using a version of Fried’s phenotype criteria operationalized to SHARE while polypharmacy was defined as taking five or more drugs per day. We found a prevalence of 40.4% non-frail, 47.3% pre-frail and 12.3% frail participants. Moreover, a prevalence of polypharmacy of 31.3% was observed, being 3 three times more prevalent in frail individuals and two times in pre-frail individuals, when compared with non-frail. Individuals with both conditions had shown higher mortality rates. Comparing with non-polymedicated non-frail individuals all the other conditions are more prone to die within 30 months. Polymedicated older and male participants exhibited also higher mortality rates. This work shows polypharmacy and frailty to be associated with a higher risk of all-cause of mortality and highlights the need to decrease ‘unnecessary’ polypharmacy to reduce drug-related issues and also the need to assess frailty early to prevent avoidable adverse outcomes. MDPI 2021-03-30 /pmc/articles/PMC8036295/ /pubmed/33808273 http://dx.doi.org/10.3390/ijerph18073580 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Midão, Luís Brochado, Pedro Almada, Marta Duarte, Mafalda Paúl, Constança Costa, Elísio Frailty Status and Polypharmacy Predict All-Cause Mortality in Community Dwelling Older Adults in Europe |
title | Frailty Status and Polypharmacy Predict All-Cause Mortality in Community Dwelling Older Adults in Europe |
title_full | Frailty Status and Polypharmacy Predict All-Cause Mortality in Community Dwelling Older Adults in Europe |
title_fullStr | Frailty Status and Polypharmacy Predict All-Cause Mortality in Community Dwelling Older Adults in Europe |
title_full_unstemmed | Frailty Status and Polypharmacy Predict All-Cause Mortality in Community Dwelling Older Adults in Europe |
title_short | Frailty Status and Polypharmacy Predict All-Cause Mortality in Community Dwelling Older Adults in Europe |
title_sort | frailty status and polypharmacy predict all-cause mortality in community dwelling older adults in europe |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8036295/ https://www.ncbi.nlm.nih.gov/pubmed/33808273 http://dx.doi.org/10.3390/ijerph18073580 |
work_keys_str_mv | AT midaoluis frailtystatusandpolypharmacypredictallcausemortalityincommunitydwellingolderadultsineurope AT brochadopedro frailtystatusandpolypharmacypredictallcausemortalityincommunitydwellingolderadultsineurope AT almadamarta frailtystatusandpolypharmacypredictallcausemortalityincommunitydwellingolderadultsineurope AT duartemafalda frailtystatusandpolypharmacypredictallcausemortalityincommunitydwellingolderadultsineurope AT paulconstanca frailtystatusandpolypharmacypredictallcausemortalityincommunitydwellingolderadultsineurope AT costaelisio frailtystatusandpolypharmacypredictallcausemortalityincommunitydwellingolderadultsineurope |